Amidst the growing threat of the second wave of corona in the country, good news has emerged. The Indian Council of Medical Research (ICMR) in one of its researches has found that the first indigenous corona vaccine (Covaxin) made in India is effective against various variants (forms) of coronavirus.
Known as (Covaxin), the Covid-19 vaccine has been manufactured by Bharat Biotech. All people aged 18 years and above have been approved to be vaccinated in the country from May 1. The research, which came just before the expansion of the immunization program in the country, has further raised hopes. The double mutant variant is probably responsible for the second wave of corona in the country.
The new variant of corona i.e. double mutant variant (B.1.617) was initially detected in India with two mutations. For the first time, a scientist in India was briefed last year and more information has been submitted to the World Health Organization recently. Last month, the Union Health Ministry had acknowledged the presence of double mutants for the first time. Since then, double mutations have been found in 10 countries including Australia, Germany, Britain, and the US.
ICMR study shows #COVAXIN neutralises against multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well. @MoHFW_INDIA @DeptHealthRes #IndiaFightsCOVID19 #LargestVaccineDrive pic.twitter.com/syv5T8eHuR
— ICMR (@ICMRDELHI) April 21, 2021
The speed of corona is increasing day by day. The daily figure of infected persons has reached nearly three lakh. Experts are on the lookout for the causes of the second wave of corona infection. Recently, the National Institute of Virology (NIV) shared some data in a meeting with laboratories in Maharashtra. Genome sequencing of 361 samples was done in the state from January to March, out of which 220 (about 61%) Were found to be of double mutant variant. According to sources, genome sequencing of 1.40 lakh samples has been done across the country.
What is B.1.617?
The double mutant variant is classified as B.1.617. Both E484Q and L452R mutations have been found. These variants have been found to be different in many countries, but this is the first time in India that the two have come together. Both mutations have been in the spike protein of the virus, which makes it easier for the virus to enter human cells.